2.22

0.45% -0.010

After Hours: 2.25 0.03 +1.35%

Tuhura Biosciences Inc (HURA)

Overview News Price History Discussions Forecast

Tuhura Biosciences Inc stock is traded at $2.22, with a volume of 491.70K. It is down -0.45% in the last 24 hours and down -3.90% over the past month. TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Previous Close:

$2.23

Open:

$2.24

24h Volume:

491.70K

Relative Volume:

0.57

Market Cap:

$141.38M

Revenue:

Net Income/Loss:

$-30.92M

P/E Ratio:

-3.6822

EPS:

-0.6029

Net Cash Flow:

$-27.39M

1W Performance:

+6.73%

1M Performance:

-3.90%

6M Performance:

+155.17%

1Y Performance:

-9.39%

1-Day Range:

$2.19

$2.38

1-Week Range:

$2.07

$2.4843

52-Week Range:

$0.41

$3.90

Tuhura Biosciences Inc Stock (HURA) Company Profile

Name

Tuhura Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

813-875-6600

Address

10500 UNIVERSITY CENTER DR., TAMPA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

HURA's Discussions on Twitter

Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HURA Tuhura Biosciences Inc	2.22	144.56M	0	-30.92M	-27.39M	-0.6029
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Citizens	Mkt Outperform
Mar-03-25	Initiated	H.C. Wainwright	Buy
Dec-19-24	Initiated	Rodman & Renshaw	Buy
Nov-05-24	Initiated	Maxim Group	Buy

Tuhura Biosciences Inc Stock (HURA) Latest News

Jun 16, 2026

Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com - Investing.com Canada

Jun 16, 2026

Jun 15, 2026

TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025 - grafa.com

Jun 15, 2026

TuHURA files IND for TBS-2025 in blood cancer study - Investing.com

Jun 15, 2026

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - PR Newswire

Jun 15, 2026

Jun 14, 2026

TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, Stock Rises Despite Wider Loss - newsline.com

Jun 14, 2026

Jun 12, 2026

HURA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Stage; Stock Gains 5.29%Margin Expansion Trends - newsline.com

Jun 12, 2026

Jun 11, 2026

TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com

Jun 11, 2026

Jun 10, 2026